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https://doi.org/10.1016/j.ccell.2019.02.002SUMMARYUndifferentiated sarcomas (USARCs) of adults are diverse, rare, and aggressive soft tissue cancers. Recent
sequencing efforts have confirmed that USARCs exhibit one of the highest burdens of structural aberrations
across human cancer. Here, we sought to unravel themolecular basis of the structural complexity in USARCs
by integrating DNA sequencing, ploidy analysis, gene expression, and methylation profiling. We identified
whole genome duplication as a prevalent and pernicious force in USARC tumorigenesis. Using mathematical
deconvolution strategies to unravel the complex copy-number profiles andmutational timingmodels we infer
distinct evolutionary pathways of these rare cancers. In addition, 15% of tumors exhibited raised mutational
burdens that correlated with gene expression signatures of immune infiltration, and good prognosis.INTRODUCTION
Undifferentiated sarcomas (USARCs) of adults are soft tissue
tumors that are among the most karyotypically complex of all
cancers (TCGA, 2017). These tumors were previously known
asmalignant fibrous histiocytomas but historically have hadmul-
tiple designations based on advances in diagnostic criteria
(Fletcher, 2014). They are diagnosed by exclusion of other sar-Significance
USARC is not a specific tumor entity but rather a ‘‘wastepap
There are limited therapeutic options for patients and the biolo
stood.We show that a genomic classification for USARC is clini
copy number and rearrangement landscapes highlight USA
haploidy, andWGD events in cancer. We also show that these t
sarcoma subtypes from The Cancer Genome Atlas, shedding
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This is an open access article undcoma entities and likely represent a final commonmorphological
endpoint of a variety of sarcomas and, possibly, other tumors
(Fletcher et al., 2001). Prognosis for these patients is poor, with
a median survival for those with advanced, metastatic disease
of approximately 12 months (Savina et al., 2017). The benefit
of systemic therapy, particularly in the adjuvant setting is contro-
versial (Linch et al., 2014). A lack of objective diagnostic criteria
has led to a dearth of studies interrogating genomic complexityer basket’’ grouping of sarcomas that cannot be classified.
gy underlying USARC tumorigenesis remains poorly under-
cally and biologically relevant. Deconvolution of the complex
RC as an exemplar model to study chromothripsis, early
umorigenic pathways are active to different degrees in other
light on pan-sarcoma mechanisms of tumorigenesis.
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in these tumors at base pair resolution. The ability to probe this
complexity is important because genomic instability is a key
catalyst in cancer evolution, fuels tumor heterogeneity, and is
relevant therapeutically (Burrell et al., 2013). The karyotypic
complexity inherent in USARCs also suggests that interrogating
and distilling structural aberrations in these tumors may yield
large returns in our understanding of the disease.
Recent work from The Cancer Gene Atlas (TCGA) has charac-
terized the cancer driver gene landscapeof a number of soft tissue
sarcoma types, including 44 undifferentiated pleomorphic sar-
comas (henceforth TCGA.USARC) using a multi-omic approach
(TCGA, 2017). Here, we sought to extend that work through whole
genome sequencing (WGS), resulting in insights into USARC
biology and evolution and potential avenues for treatment.
RESULTS
A collection of 76 tumor samples diagnosed using standard of
care were selected for investigation, based on availability of
adequate nucleic acid, and were required to be radio- and
chemotherapy naive in order to ensure high-quality, tumor-rich
specimens and to avoid confounding by prior treatment. Eight
cases were reclassified as other sarcoma entities through path-
ological review or genomic characterization and thus excluded
(STAR Methods and Figure 1A). Tumors were classified into
morphological variants (pleomorphic, spindle, epithelioid, or
mixed) according to the most recent guidelines (WHO, 2013)
for further analysis (Figure 1B).
USARCs Are Characterized by Relative Global
Hypomethylation Compared with Normal Muscle
Biologically relevant subgroups of mesenchymal tumors have
recently been identified through DNA methylation profiling (Roh-
rich et al., 2016). These molecular classification schemes hold
great promise for sarcoma clinical diagnostics and add value
to the traditional histological classification for prognostication.
To determine if molecularly defined subgroups could be identi-
fied in USARCs, we performed genome-wide methylation
profiling (EPIC array) and gene expression analysis (RNA
sequencing, Table S1) for all tumor samples for which sufficient
high-quality nucleic acid was available. Compared with adjacent
normal tissues (skeletal muscle) USARC methylomes showed
relative hypomethylation on a genome-wide scale with the ma-
jority of the signal confined to intergenic regions of the genome
and in ‘‘open sea’’ regions rather than in promoter regions or
CpG islands (Figure 1C), and this result was reproduced in the
TCGA.USARC dataset (Figure S1A).
Principal-component analysis of both the methylation and
gene expression data revealed strong separation between tumor
and normal samples; however, it failed to delineate any clear sub-
groups within USARCs (Figure 1D), and, similarly TCGA.USARC
are heterogeneous and do not represent a distinct sarcoma
subtype at the DNA methylation level (Figure S1B). Using unsu-
pervised hierarchical clustering we also found that there was
poor concordance between the methylation and the gene
expression sample clusters at a global level (Figure 1D), reflecting
the finding that global changes in methylation were more promi-
nent in non-genic regions. In addition, therewere no associations
with histological subtype.442 Cancer Cell 35, 441–456, March 18, 2019Both Mutational and Rearrangement Burden Are
Characteristics of Genomic Complexity in USARCs
We then analyzed 52 of the USARC samples using WGS, which
were sequenced to an average depth of 703 along with DNA
from blood from the same patients sequenced to 303 depth
(Table S1). Somatic variant calling was performed using a vali-
dated suite of software and bespoke post-processing filters.
Per sample, the median number of single nucleotide variants
(SNVs) was 4,741 (range: 2,164–32,108) (Table S1), of indels
was 449 (range: 180–20,073) (Table S1), and of rearrangements
was 166 (range: 23–514) (Table S1). A further extension cohort of
16 samples of USARCs (Table S1) were sequenced to a mean
target depth of 4033 on a cancer gene exome panel covering
3 Mb of the genome, including intronic coverage of TP53, RB1,
ATRX, and CDKN2A.
USARCs present a relatively lowmedian SNV/indel mutational
burden and a highmedian number of rearrangements and result-
ing copy-number alterations (Figure S1C). However, a subgroup
presented with high SNV/indel and low rearrangement burdens.
We thus classified USARCs into three molecular subgroups:
mutation high—rearrangement low (mutHi-rearrLo); mutation
low—-rearrangement high (mutLo-rearrHi); and mutation low—
rearrangement low (mutLo-rearrLo; Figure 1E, Table S1). Of the
45 tumors demonstrating 15,000 or fewer SNV/indel mutations
across the genome, 33 patients harbored 100 ormore rearrange-
ments per tumor (mutLo-rearrHi group). In contrast, 7 tumors
demonstrated a hypermutator phenotype with a minimum of
15,000 SNV/indel mutations per tumor (>5 mutations per Mb;
median 28,370), all of which had a relatively low rearrangement
burden (median 68) (mutHi-rearrLo group). The third molecular
subgroup consisted of 12 tumors with modest rearrangement
and mutational burdens in comparison with the others (mutLo-
rearrLo). Extension samples were classified as mutation high
(tMutHi) or mutation low (tMutLo).
Mismatch Repair Deficiency in the Muthi-rearrLo
USARC Subgroup
The finding that13% (n = 7) of USARCsamples had an elevated
mutational burden prompted further investigation. We found
somatic driver SNVs within MSH2 in two cases (PD26873a and
PD26876a), both with somatic copy-number loss of the wild-
type allele (Table S1). However, we also observed aberrations
inMSH2, includingpromotermethylation (PD26868a; FigureS2A)
and a predicted disruptive translocation on the forward strand
in intron two associated with loss of heterozygosity (LOH)
(PD26866a Figure S2B). A fifth patient (PD31196a) was found
to have a pathogenic germline mutation in MSH6 (p.V878A)
with somatic loss of the wild-type allele in the tumor. All five of
these tumors exhibited mutational signatures of mismatch repair
(MMR) deficiency (signatures 6, 15, 26, and 40, Figure S2C) and
protein loss of one or both of MSH2 and MSH6 (Figure S2D).
Sample PD31203a showed a mutational signature (signature
30) that strongly matched the base excision repair NTHL1 defi-
ciency pattern (Figure S2E), previously only seen in a breast can-
cer (Nik-Zainal et al., 2016) and an osteosarcoma (Behjati et al.,
2017). A rare pathogenic germline heterozygous nonsense
mutation of NTHL1 (pQ90*) with somatic loss of the wild-type
allele was confirmed in this patient. Finally, PD26882a showed




Figure 1. Molecular Classification of USARCs
(A) Alluvial diagram showing tumor diagnosis reclassification following expert pathological review. UPS, undifferentiated pleomorphic sarcoma; USARC, un-
differentiated sarcoma; UCS, unclassified sarcoma; SCS, spindle cell sarcoma; S, spindle; P, pleomorphic; E, epithelioid; MPNST, malignant peripheral nerve
sheath tumor; DDLPS, dedifferentiated liposarcoma; M-SFT, malignant solitary fibrous tumor; Ped. SCS, pediatric spindle cell sarcoma. Numbers indicate the
number of samples for each subtype.
(B) H&E staining of four representative USARC subtypes. Scale bars, 250 mm.
(C) Mean methylation of probes categorized by genomic position (left) or position relative to CpG islands (right), in USARC samples (orange) and normal adjacent
tissue (green); *q < 0.05, **q < 0.01, ***q < 0.001. Boxes show lower quartile, median and upper quartile; lines denote furthest point within 1.53 the interquartile
range away from the box; points denote data further than 1.53 the interquartile range away from the box.
(D) Principal-component analysis of tumor (orange) and normal (green) samples for both methylation array data (left) and RNA sequencing data (right) as well as
shared hierarchical clustering of RNA and methylation data (center).
(E) Scatterplot of rearrangement burden (x axis) against SNV/indel burden (y axis) of USARC samples from WGS. Samples were categorized into three groups:
mutation high, rearrangement low (mutHi-rearrLo, purple), mutation low, rearrangement high (mutLo-rearrHi, red), and mutation low, rearrangement low (mutLo-
rearrLo, blue). Decision boundary is shown as a dashed line. Filled circles are individual data points, ovals 50% probability intervals.
(F) Number of samples that haveR1 rearrangement in genomic windows of 1Mb (top), number of samples that have chromothriptic regions overlapping genomic
windows of 1 Mb (middle), and rearrangement partners of rearrangements within regions that are significantly enriched (bottom). Regions with significant
enrichment (q < 0.2) are labeled.
See also Figures S1–S3 and Table S1.
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Figure 2. Integration of Driver Events in USARCs
(A) Heatmap showing significant recurrently amplified or deleted regions (GISTIC q < 0.1). Known cancer driver genes in amplified regions are labeled in blue and
those in deleted regions are labeled in red. Lengths of significant regions (Mb) are indicated above the heatmap, with –log2(q values) below.
(legend continued on next page)
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with almost pure C > T transitions in a CpG context, likely caused
by spontaneous deamination of methylated cytosines (Alexan-
drov et al., 2018). Such a strong activity of signature 1 andwithout
evidence of MMR deficiency raised the possibility of failure of
repair of the deaminated cytosines. This was confirmed by the
discovery of biallelic inactivation of the DNA glycosylase gene
MBD4 (Figure S2F). MBD4 prevents mutability at CpG sites and
is a binding partner of the MMR protein MLH1 (Bellacosa et al.,
1999). To the best of our knowledge, this is the first description
of defective MBD4-associated DNA repair in sarcomas.
TP53, RB1, CDKN2A, ATRX, and 5p15.33 (TERT)
Rearrangements Are Recurrent
Leveraging the higher resolution of WGS, we called putative
structural variants and scrutinized these in order to identify po-
tential cancer driver gene events.
As fusion genes are characteristic of many sarcoma subtypes,
we first looked for structural variants causing gene fusions. Re-
sults of these analyses suggest that oncogenic chimeric fusions
are rare events in the pathogenesis of USARCs (Table S1).
Conversely, for identification of recessive mechanisms, we
sought truncating rearrangements and overlapped these regions
with known recessive cancer genes (Forbes et al., 2017). We
identified 51 recurrently rearranged genes, 9 of which are known
tumor suppressor genes (Table S1). In particular, recurrent
disruptive rearrangements were identified in TP53, RB1, and
ATRX. Using a bespoke tool for chromothripsis identification
we noted that, while the TP53 region is highly rearranged, only
1/23 rearranged samples have been identified as chromothriptic
in that region compared with 5/9 samples with ATRX rearrange-
ments (Fisher’s exact test, p < 0.01, odds ratio = 23.5, Fig-
ure S2G). These data suggest that chromothripsis is an infrequent
mechanism of TP53 disruption in USARCs and that inactivation
of tumor suppressor genes rather than activation of oncogenes
is the sine qua non of the USARC rearrangement phenotype.
A gene-agnostic method was then used to widen our search
for recurrently rearranged regions. Three genomic windows
incorporating 5p15.33, 17p13.1, and 17p11.2 were identified as
harboring significant rearrangements across samples (false
discovery rate [FDR]: q < 0.2) (Figure 1F). The 17p13.1 region har-
bors TP53.
Two other recurrently rearranged regions containing canonical
cancer driver genes RB1 and CDKN2A were identified by this
method but were not significant following multiple testing
(FDR: qR 0.2).
There was an enrichment of diverse rearrangements on the
boundaries of the TERT gene (5p15.33), which encodes the cat-
alytic subunit of telomerase (Figure S3A). One mechanism of
activating TERT is through rearrangements that colocalize
TERTwith distant enhancer regions, so-called ‘‘enhancer hijack-
ing’’ (Peifer et al., 2015). By overlapping the genomic positions of
the boundaries of structural breakpoints with the dbSUPER
(Khan and Zhang, 2016) database of 91 human andmouse tissue(B) SNV and indel mutational burden barplot (top) and copy-number alterations,
known cancer genes (middle), with clinical and genetic covariates (bottom). Red te
CC, cell cycle; tel, telomere maintenance; mTOR, mTOR signaling pathway; me
platform, burden group, and mutational status.
See also Table S2.types, we identified that of the 13 rearrangements (8 transloca-
tions, 4 inversions, and 1 tandem-duplication; 7 downstream, 5
upstream, and 1 within TERT) within 100 kb of TERT, 8 rear-
rangements have a partner region that directly overlaps or is
within 500 kb of a super enhancer in all tissues or muscle tissues
only. Furthermore, in those samples with such rearrangements
we found that the expression of TERTwas significantly increased
(Figure S3B). These data strongly suggest that TERT enhancer
capture is being tagged by rearrangements in the region.
Because TERT is known to be dysregulated through multiple
mechanisms, this finding prompted a search for other potential
mechanisms of TERT activation. There were no predicted
TERT fusion events. However, two cases (PD26857a and
PD31187a) demonstrated hypermethylation of the repressive
element within the TERT promoter locus (Figure S3C). We also
found evidence for increased telomere length (tumor:normal
ratio) in the majority of samples and disruption in either ATRX
or DAXX or in the TERT promoter (Figures S3D and S3E).
To determine the significance of rearrangements in the
17p11.2 region we correlated gene expression for all genes in
the cytoband with rearrangement status. This revealed two
genes with significantly altered expression namely GID4 and
RASD1 (Figure S3F); GID4 encodes a coactivator of RNA poly-
merase II and has increased expression in the rearranged
samples (p = 2.0 3 103, q = 5.6 3 103). RASD1, encoding a
member of the RAS family, has a significantly reduced expres-
sion in rearranged samples (p = 5.9 3 104, q = 2.6 3 103). In
line with this observation, it has previously been proposed that
RASD1 is a tumor suppressor gene in some cancer types (Gao
et al., 2017).
Integration of Driver Mutations, Rearrangements, and
Copy-Number Variants
Using a statistical model for mutational driver analysis we
found four recurrent driver genes from WGS, all of which are
known cancer genes (TP53, RB1, PTEN, and ATRX, q < 0.2;
Table S2). In addition, using this method MEN1 was identified
as somatically mutated in four samples (6%). MEN1 mutations
have not previously been reported in sarcomas and have been
described only occasionally in benign smooth muscle tumors
and rarely in lipomas (Forbes et al., 2017). These mutations
included two frameshift deletions (PD26863a p.F370Sfs*65;
PD26873a p.R521Gfs*43), a nonsense mutation (PD31196a
p.R532*) and an in-frame deletion (PD26877a p.G168_L173de-
linsV). Copy-number calling (Table S2) followed by recurrent
copy-number analysis revealed significant recurrent altered re-
gions of the USARC genome including amplification of the
known sarcoma driver oncogenes JUN and RICTOR, and dele-
tion of cancer driver genes such as TP53, RB1, CDKN2A,
CBFA2T3, STK11, TCF3, and CYLD (GISTIC, q < 0.1; Figure 2A;
Table S2).
We then integrated mutational and structural variants into a
comprehensive USARC driver mutation landscape (Figure 2B),SNVs, small indels, structural variants and promoter methylation alterations in
xt indicates driver genes identified by dNdSCV (q < 0.2). stab, genome stability;
n, MENIN pathway; repair, DNA repair. Samples are ordered by sequencing




Figure 3. Implications of Increased Tumor Mutational Burden
(A) Venn diagram of predicted pathogenic variants frommutHi samples identified from targeted sequencing (left) and identified fromWGS in regions overlapping
the design of the targeted baitset (right).
(B) Variant allele frequency (VAF) of all variants (left) or variants only observed by targeted sequencing (right).
(C) Overall survival of patients stratified by mutational burden and with a univariate Kaplan-Meier model.
(D) Multivariate accelerated failure time model for progression-free survival with size of tumor, resection status, and burden group as covariates.
(E) Gene set enrichment analysis for interferon gamma response (green) and antigen presentation (purple) pathways using both DNA methylation (top) and gene
expression (bottom) data comparing the mutHi-rearrLo group against all others. See also Table S3.noting from the WGS data that up to 50% of driver events in
TP53, RB1, and ATRX would have been missed if only exome
data were available for the cohort. Furthermore, from a poten-
tial therapeutic standpoint, mutational profiling and manual
curation of driver variants revealed that 33% (n = 17) of tumors
harbored mutations in genes encoding proteins upstream of
mammalian target of rapamycin (mTOR) in the signaling
cascade. These included truncating events in PTEN (n = 10),
TSC1 (n = 2), and TSC2 (n = 2), as well as a hotspot mutation
in PIK3CA (p.H1047R).
Hypermutation Fuels Subclonal Mutations in
Cancer Genes
Data showing that sarcomas have relatively modest mutational
burdens compared with other cancer types (Campbell et al.,
2017) prompted an investigation to determine whether high-
depth sequencingmight reveal awider spectrum of cancer driver
genes than identified by our 703 depth for WGS. We therefore
sequenced our 7 hypermutated samples and an extension
cohort of 16 new USARC samples (Table S3) to a mean target
depth of 4033 on a cancer driver gene panel. Analysis of the
hypermutated samples revealed that up to 18% of variants had
not been reported in the WGS (Figure 3A) and were dominated
by subclonal mutations (Figure 3B). In the extension cohort,446 Cancer Cell 35, 441–456, March 18, 2019the spectrum of driver genes mirrored that of the WGS data (Fig-
ure 2B), which is also reflected in the TCGA.USARC samples.We
also found three hypermutated samples (19%) in the extension
cohort, one of which harbored a nonsense mutation of PALB2
(pE331*). Two samples lacked an identifiable causative mutation
in either the somatic or germline genome using the targeted
approach.
Utility of a Genomic Classification for USARCs
The histological classification of USARCs has a chequered his-
tory and is based on exclusion of other sarcoma entities
(Fletcher, 1992). There is a pressing need to address the incon-
sistencies of the current classification because the morpholog-
ically heterogeneous nature of USARCs and its genomic
complexity have resulted in a deficiency in identification of
biomarkers that could inform risk stratification and clinical man-
agement strategies. To test whether classifying USARCs by
mutational burden might have prognostic significance we
conducted a survival analysis using both a univariate analysis
(Figure 3C) and a robust parametric statistical model using
multivariate clinical andmolecular data including themutational
subgroups (Figure 3D). This revealed that the mutHi group
showed significantly better progression-free and metastasis-
free survival (Table S3) compared with mutLo groups. As
A B
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Figure 4. Rearrangement Signatures
(A) Rearrangement diversity and counts in the USARC cohort, classified by rearrangement size and rearrangement class.
(B) Five rearrangement signatures identified by non-negative matrix factorization (NMF); USARC.RS1, clustered translocations (tloc, purple); USARC.RS2, small
unclustered tandem duplications (TD, green), inversions (inv, red), and deletions (del, blue); USARC.RS3, large unclustered TDs, invs, and dels; USARC.RS4,
large clustered TDs, invs, and dels; USARC.RS5, unclustered tlocs. x axis, strength of each rearrangement class in each signature.
(C) Contribution of activities of each signature per sample (left) and cosine similarities between published breast cancer rearrangement signatures (BRCA.RS1-6)
and USARC rearrangement signatures (right). See also Figure S4 and Table S4.expected, metastasis was found to have a significantly detri-
mental effect on overall survival (Table S3). There was no
significant survival effect associated with any of themost recur-
rently mutated genes after accounting for clinical confounders.
Furthermore, pathway analysis revealed significant enrichment
for immune-related pathways in mutHi compared with other
samples, suggesting an altered immune response in those
samples with a high tumor mutational burden (Figure 3E). The
same trend was observed in TCGA hypermutators, although
the sample size (n = 3) was not sufficient for a significant result
(data not shown).
Rearrangement Signatures Reveal Distinct Patterns of
Structural Variation
The rearrHi and rearrLo molecular subgroups highlight the diver-
sity in rearrangement burden in USARCs, and, indeed, the nature
of structural rearrangements in USARCs is also varied (Fig-
ure 4A). We sought to investigate the rearrangement processes
underpinning this landscape. To this end we extracted recurring
rearrangement signatures (Nik-Zainal et al., 2016) based on
the nature, size distribution, and local clustering of structural
variants. Using a non-negative matrix factorization mathemat-
ical framework, we identified five predominant signatures
(USARC.RS1-USARC.RS5; Figure 4B; Table S4). Interestingly
USARC.RS1 and USARC.RS5 were strongly dominated by
translocations and showed a comparative dearth of other rear-
rangement classes. These signatures are differentiated from
each other by the presence of proximity clustering of the
breakpoint regions, suggestive of alternate rearrangement
mechanisms (Glodzik et al., 2017). The remaining signatures
(USARC.RS2 to USARC.RS4) showed a more varied pattern of
rearrangement classes.By contrasting these five sarcoma signatures with a published
WGS dataset of breast cancer (Nik-Zainal et al., 2016), we found
that USARC.RS1, USARC.RS4, and USARC.RS5 have previ-
ously been identified, suggesting common mechanisms driving
structural variation between these diverse cancer types (Fig-
ure 4C). Unsurprisingly, the activities of the two signatures of
clustered rearrangements, USARC.RS1 (clustered transloca-
tions) and USARC.RS4 (clustered tandem duplications, inver-
sions and deletions), were associated with the number of
chromothriptic chromosomes (linear regression, p = 3.3 3
105, q = 8.7 3 104; p = 1.1 3 102, q = 8.7 3 102, respec-
tively; Figure S4). USARC.RS2 signature activity was seen
in 52% of samples (median exposure = 7%, interquartile
range [IQR] = 0%–13%) and is characterized by unclustered
co-occurring megabase scale tandem duplications, deletions,
and inversions. USARC.RS3, which was seen in 92% of samples
(median exposure = 30%, IQR = 23%–45%), has a similar overall
pattern to USARC.RS2, but shows a different segment size
distribution favoring longer lengths, possibly indicating divergent
mechanisms of generation. This intriguing set of results called
for a deeper understanding of the impact of extensive and com-
plex structural variation on the copy-number profiles of USARCs.
The Genomic Complexity of USARCs Is Unraveled Using
Copy-Number Signatures
Accurate inference of the nature and role of copy-number aber-
rations in most samples was hindered by substantial complexity,
demonstrated by multiple large and small chromosomal gains
and losses across the genome and compounded by whole
genome duplication (WGD) events. We adopted a pragmatic
approach that deconvoluted complex copy-number profiles
into various distinct operative copy-number processes andCancer Cell 35, 441–456, March 18, 2019 447
AB
C D E F
G H
Figure 5. Copy-Number Signatures
(A) Seven copy-number signatures identified using NMF; amp, amplified (CNR 1, orange); dup, duplicated (3%CN% 4, purple); neut, neutral (CN, 2, green); del,
deletion (CN% 1, blue); homdel, homozygous deletion (CN, 0, gray); het, heterozygous. x axis, strength of each copy-number class in each signature.
(legend continued on next page)
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then compared these across samples to make inferences about
their development and effects. Copy-number profiles were sum-
marized into a metric by classifying copy-number segments
according to size, LOH status, and total copy number. This
framework identified seven copy-number signatures (CNS1-7;
Figures 5A and 5B; Table S5). CNS1 is a signature indicative of
amplified LOH, which correlates with two or more WGD events
(asymptotic Wilcoxon-Mann-Whitney test, Z = 4.84, p =
4.5 3 107, q = 2.6 3 107; Figure 5C). CNS2 is a signature of
duplicated LOH that may signify a single WGD. CNS3 is a signa-
ture of hypodiploid tumors (no evidence of WGD) with a large
proportion of unaltered segments, and some small amplifica-
tions and large deletions. CNS4 is a signature of copy neutral
LOH. CNS5 has features of amplification with retention of hetero-
zygosity and neutral LOH segments. CNS6 is a complex copy-
number signature comprising large heterozygous neutral and
duplicated segments with smaller LOH segments of multiple
copy-number states. CNS7 is the signature that is observed in
the highest proportion of samples (67% of samples) and is a
signature of a single WGD. These features of WGDwith retention
of heterozygosity and losses seen in CNS6 and CNS7 appear to
fit a described model of tetraploidization followed by genomic
losses, thereby generating an aneuploid cell state, particularly
in a p53- and/or RB1-deficient background (Davoli and de
Lange, 2012).
Furthermore, our earlier integrative mutational analysis re-
vealed that 68% of tumors harbored a putative disruptive event
in TP53, and that abrogation of TP53 was significantly associ-
ated with activity of CNS1 (LOH with two or more WGDs) (Krus-
kal-Wallis test, p = 9.23 104, q = 1.33 102; Figure 5D). PTEN
mutations are associated with an increased activity of the signa-
ture of copy neutral LOH, CNS4 (Kruskal-Wallis test, p = 3.9 3
103, q = 4.3 3 102), and activity of CNS4 is also correlated
with tumor mutational burden (linear regression, p = 5.3 3
103, q = 5.1 3 102). The number of chromothriptic chromo-
somes in a sample is significantly correlated with activity of
CNS5 (linear regression, p = 7.2 3 107, q = 2.6 3 105; Fig-
ure 5E) and samples that harbor chromothriptic chromosomes
are enriched in the rearrHi group but are not associated with
metastasis (Figures S5A and S5B). Activity of CNS5 across the
cohort is also highly similar to the activity of the rearrangement
signature of clustered translocations, USARC-RS1 (cosine simi-
larity = 0.82; linear regression, p = 3.2 3 108, q = 5.8 3 106;
Figure 5F). We then sought to determine the effects of these
intriguing copy-number patterns on gene expression. We found
a consistent and strong gene dose effect of the DNA copy num-
ber on RNA expression (Figure S5C); however, there was no
consistent pathway enrichment correlated with copy-number
groups, compatible with the fact that most of the copy-number(B) Activities of copy-number signatures (CNS) per sample, with associated prop
(C) Density plot of CNS1 activity stratified by whether the sample has one or fe
(WGD32). Thickness of gray region indicates density. Small vertical lines, data p
(D) Density plot of CNS1 activity stratified by TP53 mutation status.
(E) Scatterplot of CNS5 activity against number of chromothriptic chromosomes
(F) Scatterplot of CNS5 activity against USARC.RS1 activity. Gray line indicates
(G) Diversity estimates of CNS in TCGA sarcoma subtypes and our USARC coho
(H) CNS5 activity stratified by tumor type in TCGA.
Boxes show lower quartile, median, and upper quartile; lines denote furthest point
S6 and Table S5.events are private events. Further, linear modeling of gene
expression in genes of interest identified a significant relation-
ship between gene expression and copy number in five genes
(TP53, RB1, CDKN2A, PTEN, and TERT; q < 0.05), but no signif-
icant association between promoter methylation and gene
expression once copy number is accounted for (q > 0.05).
USARCs Show Extreme Copy-Number Heterogeneity
To explore the extent to which the copy-number signatures were
operative in other samples, we compared our findings with a
cohort of 320 sarcomas of multiple subtypes including samples
from TCGA, the allele-specific copy-number states of which
were extracted fromWGS and high-resolution SNP arrays. Three
signatures were identified in this validation cohort (Figures
S6A–S6D), all three of which were also identified in USARCs
(CNS1, CNS3, and CNS7). CNS3, which is a signature of
hypodiploid tumors, was highly operative in synovial sarcoma
and a spectrum of low-grade sarcomas, both of which have
low karyotypic complexity and rarely show WGD.
We then quantified the within-sample copy-number heteroge-
neity among different sarcoma types using a diversity index. This
demonstrated that the lowest copy-number diversity is seen in
synovial sarcoma, which is typically dominated by CNS3. The
two USARC cohorts have the same degree of copy-number di-
versity, being the highest among various sarcoma types and is
indistinguishable from the copy-number diversity seen in myxo-
fibrosarcoma (MFS) (Figure 5G). This indicates that multiple
processes generate copy-number alterations in USARCs, lead-
ing to a highly chaotic and varied copy-number landscape within
each sample and across samples. Interestingly, dedifferentiated
liposarcoma (DDLPS), a high-grade sarcoma that can show
similar morphological heterogeneity and pleomorphism to
USARCs showed a significantly lower CNS diversity (Mann-
Whitney test; p = 0.003). This reduced diversity in DDLPS is re-
flected by apredominance ofCNS5 in this tumor type (Figure 5H).
Chromothripsis, particularly of chromosome 12, is a key driver
event in DDLPS pathogenesis (Garsed et al., 2014), which is
identified in these samples through the observation of CNS5.
These findings illustrate that DDLPS samples have more similar
characteristics to each other than USARC samples do.
Pseudohaploidization Is Recurrent in USARCs
In view of the large proportion of our cohort of USARC samples
bearing different spectra of LOH and the identification of copy-
number signatures strongly defined by an LOH pattern, e.g.,
CNS4, we investigated this phenomenon in greater detail. We
found that 14 tumors (27%) in our USARC cohort demonstrate
widespread LOH (>50% genome LOH) and that 3 tumors exhibit
striking near-genome-scale haploidy (>90% genome LOH).ortion of the genome that shows LOH, and molecular classification groups.
wer genome doubling events (WGD<2) or has two genome doubling events
oints. Large vertical lines, median.
. Gray line indicates linear fit.
linear fit.
rt.
within 1.53 the interquartile range away from the box. See also Figures S5 and
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AC
B Figure 6. LOH and Haploidization Are
Frequent Events in USARCs
(A) Histogram of DNA content, measured as inte-
grated optical density (IOD) (x axis), for cell nuclei
from PD26890. Proportion of genome LOH = 44%.
2c, median IOD of normal cell nuclei.
(B) Histogram of DNA content for cell nuclei from
PD26873. Proportion of genome LOH = 93%.
(C) Proportion of samples within the USARC WGS
cohort that are LOH (y axis) in sliding windows of the
human genome of size 1Mb each separated by 100
kb (x axis). Dashed line, boundary of regions with
highly recurrent LOH (>0.8) or retention of hetero-
zygosity (<0.2). Regions with retention of hetero-
zygosity are highlighted with a horizontal black line.
Regions with recurrent LOH are labeled with puta-
tive driver tumor suppressor genes in those regions.These data suggest that haploidization may be a common event
in USARC evolution. To independently investigate this mecha-
nism, we carried out ploidy analysis to estimate both DNA
content and visualize nuclear morphology. This revealed diverse
cell states with multiple cell fractions of increasing ploidy indica-
tive of successive WGDs in samples (Figure 6A). One sample
revealed an intact near-haploid subclone that constituted 9%
of tumor cells, suggesting that the genome-duplicated clone
had not completely swept through the tumor in this sample
and might have been fueled by the near-haploid population
(Figure 6B). Large-scale haploidy has previously been described
using SNP arrays in low-grade chondrosarcoma (Bovee et al.,
2000) and in other sarcoma subtypes (Mertens et al., 1998) of
various grades.
Recurrent regions of LOH included the loci of RB1 (chromo-
some 13q14.2) and TP53 (chromosome 17p13.1) (Figure 6C),
with 88% and 63% of mutational events co-occurring with
LOH, respectively (Figure 2B), highlighting how the LOH back-
ground makes USARCs propitious to double-hits on tumor
suppressors. Conversely, there were retained regions of hetero-
zygosity on chromosomes 1, 2, 4, 5, 7, 9, 19, and 21 in >80% of
samples (Figure 6C). Proliferation rates determined by mitotic
counts did not differ between samples with and without LOH
and aberrant mitoses were prevalent in all samples (data not
shown). Finally, we investigated the relationship between LOH
and chromothripsis across our dataset and found negative
associations between CNS5, the signature of chromothripsis,
and both the proportion of genome that is LOH (linear
regression, p = 2.1 3 104, q = 3.8 3 103), and the sum of
all LOH-associated signatures, CNS1-4 (linear regression, p =
2.1 3 107, q = 2.0 3 105).
Timing of Polyploidization and Driver Mutations in
Sarcomas
To better understand the contribution of polyploidization to the
tumorigenesis of USARCs we used the copy-number data to450 Cancer Cell 35, 441–456, March 18, 2019interrogate patterns of WGD. A total of
89% of samples exhibited at least one
WGD event, and 19% of samples showed
at least two WGDs (Figure 7A). This con-
trasted remarkably with the averageWGD occurrence of 37% across multiple cancer types (Zack
et al., 2013), indicating that WGD is an important tumorigenic
event in USARCs. Mutational data were then integrated with
the WGD analysis to infer both relative and real-time timing of
WGD events. Categorizing samples by their most prevalent
copy-number signature (Figures 7B–7D) revealed differential
WGD timing in USARCs; groups of samples with potentially mul-
tiple WGDs, CNS5 and CNS1, have predominantly early first
WGD, whereas CNS4 tumors have predominantly late WGD
events, with the exception of two of the hypermutators in that
group. The molecular timing of second WGDs, in cases where
WGD was amenable to timing (Table S6), showed that most
occurred close to diagnosis, whereas the firstWGD arose across
a range of molecular times. The time between the first and
second WGD is often in the order of decades, while the time
between second WGD and diagnosis is considerably shorter.
This analysis was extended to the sarcoma cohort of TCGA
(Figure 7E), that showed the largest range of WGD times in
USARCs, and confirmed early WGD in CNS5, drastically con-
trasting the late WGD in DDLPS of the same signature group.
Timing of driver mutations demonstrated that the vast majority
of driver mutations occurred before the first WGD in USARCs
(Figure 7D). Of interest in the USARC cohort are three samples
with age of diagnosis <40 years (within the 5% quantile of diag-
nostic age of USARCs andMFS; mean = 67.8 years), all of which
have a late WGD. Indeed, there is a trend toward late WGD in
patients with a younger age at diagnosis (linear regression,
p = 0.066). Extending this analysis to the sarcoma cohort of
TCGA (Figures 7E and S7A–S7F) revealed an enrichment for a
second WGD (CNS1) in USARC/MFS. WGD was predominantly
late in CNS5 DDLPS, and predominantly early in CNS5 USARC,
confirming the results in our cohort. Remarkably, in CNS1, which
was associated with TP53 LOH, the two TP53 mutations
amenable to timing in USARCs seemed to have occurred
posterior to the first WGD but before the second WGD, suggest-





Figure 7. Timing of Genome Duplication and Driver Mutations
(A) The number of WGD determined by the mode of the major allele in a sample (mode 1, diploid, 03WGD; mode 2, tetraploid, 13WGD; mode >2, octoploid,
23WGD) matches inference from the spread of the samples in the proportion of LOH versus ploidy space.
(B) Time of WGD (circles/squares, mean timing per sample. Square indicates more than 10,000 SNVs and circle is less than 10,000 SNVs; vertical colored
bars, 95% confidence intervals on the mean values) in years before diagnosis, split by predominant copy-number signature in USARC cohort whole
genomes.
(C) Time of WGD in the sarcoma cohort of TCGA, split by tumor type.
(D) Relative timing of driver mutations (colored circles) and WGD events (empty/gray circles) using the mutations as a molecular clock in USARC cohort whole
genomes. Vertical bars, 95% confidence intervals. Samples split by predominant copy-number signature.
(legend continued on next page)
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diploid copy-number state, a further hit was necessary to rein-
state TP53 inactivation.
USARCs Are Heterogeneous Tumors with Evidence for
Subclonal WGD
Our data indicate that polyploidization is a key event in USARC
tumorigenesis except for a small outlier group of high-grade tu-
mors without evidence ofWGD as estimated byWGS (CNS3). To
address this conundrum, we used ploidy cytometry analysis,
which revealed that 4/6 ‘‘non-genome duplicated’’ CNS3 sam-
ples contained substantial cell fractions with one or more WGD
events, ranging from 36% to 71% of cells in a sample (Figures
8A and 8B). This discrepancy of ploidy results between WGS
and cytometry could be methodological as our WGS algorithm
is blind to subclonal WGD, but it also reinforces the heteroge-
neous nature of these tumors as different regions from the
same tumor were used for these two analyses. PD31204 con-
tained large peaks of a relatively diploid clone (44% of cells),
and sizable fractions of cells with one or two WGD events
(34% and 11% of cells, respectively) (Figure 8B). These results
demonstrate sequential subclonal WGD events in samples that
have predominantly diploid populations of cells, which suggest
that these tumors were diagnosed before the onset of a potential
clonal sweep in which the WGD population of cells dominated,
and that WGD and second WGD events are probably more
prevalent in USARCs than our estimates using WGS of a single
tumor region suggest.
DISCUSSION
Through the parallel analyses of WGS, DNAmethylation profiling
and gene expression we have generated a comprehensive mo-
lecular and clinical landscape of USARCs. USARCs with high
mutational burden (mutHi) were found to be enriched for activa-
tion of immune pathways at both the DNA methylation and gene
expression levels. More effective therapeutic approaches are
desperately needed for USARC patients and we propose that
classifying USARCs by mutational burden is clinically relevant.
Furthermore, hypermutation and the recurrence of mutations in
mTOR signaling genes open up alternative avenues for stratifica-
tion and immunotherapy clinical trial design for these patients.
We have illuminated the karyotypic complexity in USARCs
through the development of a copy-number signature frame-
work that has proved to be a practical method to infer evolu-
tionary dynamics at a structural level. By integrating the results
from copy-number signatures, mutational timing, and ploidy
analysis we deduced four potential routes to USARC tumorigen-
esis, all beginning with early driver mutations, preceding any
WGD event (Figure 8C). In particular, CNS4 is indicative of
WGD in an inferred precursor cell that has a near-haploid chro-
mosomal state. This genomic loss is likely achieved through a
single mis-segregation event such as a mitotic error rather
than through progressive loss. Live cell-imaging experiments
of chromosomally unstable cells have demonstrated that mis-(E) Relative timing of driver mutations andWGD events in the sarcoma cohort of TC
tumor type. Vertical bars, 95% confidence intervals.
Boxes are delimited by first and third quartiles; the thick segment shows themedia
from the box. See also Figure S7 and Table S6.
452 Cancer Cell 35, 441–456, March 18, 2019segregation during anaphase can lead to two aberrant daughter
cells; one that is hypoploid, and another that is hyperploid due to
sequestration of a lagging chromosome in a micronucleus,
which may be susceptible to chromothripsis (Huang et al.,
2012). This suggests that there could be a dichotomous relation-
ship between cells that are hypoploid (genome-wide LOH) and
those in which chromothripsis can occur. Indeed, USARC sam-
ples with large-scale LOH show a negative association with
signatures of chromothripsis, suggesting a different evolutionary
trajectory between LOH and chromothriptic samples. Alterna-
tively, chromothripsis may be selected against in near-haploid
cells due to the potential introduction of large regions of
homozygous deletions. The strong association of CNS5 with
USARC.RS1, but not USARC.RS4, demonstrates that in USARC
chromothripsis most often generates translocations, and sug-
gests that there may be other signatures of chromothripsis that
remain to be discovered. On a permissive background of TP53
or RB1 inactivation, such widespread genomic loss could lead
to a precursor cell state with a near-haploid genome as seen,
for example, in samples PD31196a and PD26920a. These losses
likely act as a second hit in a genome-wide fashion, unmasking
multiple potent pathogenic somatic or recessive germline vari-
ants simultaneously, thus dramatically increasing the fitness of
an incipient cancer cell in one crisis event. Subsequent WGD
through telomere-crisis-induced endoreduplication potentially
increases the evolutionary space within which such a cell can
optimize the dosage of various genes without risking further
haploidy or loss of any survival-critical genes (Davoli and de
Lange, 2012), and, in fact, we observed gene-dosage effects
dependent on copy number through our integrative analysis.
Conversely there is no significant association between methyl-
ation status of driver genes and gene expression once copy
number is accounted for. Furthermore, WGD dramatically accel-
erates tumor development leading to diagnosis soon after WGD
in some cases of USARCs. In other cases, the first WGD event
ranges from just before diagnosis to multiple decades before
diagnosis, suggesting that other factors contribute to rapid
tumorigenesis in some tumors but not in others. In contrast, a
second WGD event is consistently late in the tumor’s history,
sometimes decades after the first duplication and occurring
just before diagnosis. This long latency provides a clinically rele-
vant time frame for intervention should the early driver mutations
be amenable to detection in the blood circulation. Key features
from the sequencing data corroborated by DNA ploidy experi-
ments, mutational timing, and cytogenetic findings expand the
view that WGD is a recurrent phenomenon in USARCs and is a
potential transformation event instrumental in their development.
These new models of sarcoma development demonstrate
likely punctuated evolutionary trajectories and provide insights
into how patterns of LOH and copy-number gain sculpt the
sarcoma genome. Future work on larger cohorts collected pro-
spectively may elucidate other mechanisms underpinning the
aberrant copy-number landscape in sarcomas and may yield
further undiscovered copy-number signatures. There is also aGA. Samples split by predominant copy-number signature, and subdivided by
n; and whiskers extend to the last data points within 1.5 of the box length away
Figure 8. Evolutionary Pathways in USARCs
(A) Proportion of cells within a sample with no WGD (03WGD), one WGD (13WGD), or two WGDs (23WGD) using cytometric ploidy analysis, for six samples
estimated to be non-WGD through WGS.
(B) Representative examples of ploidy results for CNS3 (diploid) samples. Ploidy displayed as integrated optical density (x axis) and nuclear perimeter (y axis) of
each nucleus.
(C) Proposed pathways of USARC tumorigenesis. Driver mutations (TP53 and RB1) are early events in USARCs. Haploidization pathway: extreme anaphase
mis-segregation associated with near-genome-wide haploidy, which is rescued by WGD, leading to a CNS4 pattern. Genomic loss pathway: less extreme
anaphase mis-segregation generates large areas of LOH. Three signatures (CNS3, CNS2, and CNS1) that are variations of this LOH pattern but differentiated
from each other by subsequent WGD. Chromothripsis pathway: anaphase mis-segregation or anaphase lagging could also lead to chromosomal micro-
nucleation. CNS5 is a signature of this process followed by WGD. Endoreduplication pathway: a tumor cell may undergo WGD with relatively few other copy-
number alterations: CNS7.requirement to refine these models by investigating karyotypic
instability atmulti-region and single-cell resolution to understand
better the operative dynamics of tumor progression through
copy-number evolution.ETHICS
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to the Lead Contact, Nischalan Pillay (n.pillay@ucl.
ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patient Samples
Patient tissues and data originated from the Royal National Orthopaedic Hospital biobank, pathology archives and London Sarcoma
Service databases. Patient samples were obtained from the Stanmore Musculoskeletal Biobank, a satellite of the UCL/UCLH
Biobank (HTA Licence Number 12055), which was approved by the National Research Ethics Committee (reference 15/YH/0311).
This specific study was approved by the NHS Health Research Authority (REC reference 16/NW/0769). Informed consent was
obtained from all patients.
Case Selection
The pathology archives were searched for sarcomas ICD coded (http://www.who.int/classifications/icd/en/) as undifferentiated sar-
coma, pleomorphic sarcoma or spindle cell sarcoma NOS. Only cases where both consent and frozen tissue and matching germline
material were available were included. A total of 61 caseswere identifiedwhere adequate nucleic acid was available. Four caseswere
excluded by pathology review (R.T and N.P) and immunohistochemistry profiling as they represented other sarcoma types. A further
four cases were excluded on analysis of WGS results as they bore molecular hallmarks of other sarcoma types (viz. dedifferentiated
liposarcoma, malignant peripheral nerve sheath tumor and malignant solitary fibrous tumor). A total of 53 cases of undifferentiated/
unclassified sarcoma were included for further study. Formalin fixed, paraffin embedded tissue blocks of the tumors that were
sequenced were used for immunohistochemical and image cytometry analysis.
METHOD DETAILS
Tissue Processing and DNA Extraction
Tumor samples were retrieved from liquid nitrogen stores, embedded in Tissue-Tek OCT and sectioned on a cryostat. For each sam-
ple, an initial 5 mmhematoxylin and eosin (H&E) stained section was cut. Microscopic examination of tumor type and tumor cellularity
was estimated by a pathologist (N.P). A minimum tumor content of 50%was required for inclusion in the study. Some cases required
macrodissection to enrich for tumor content. Twenty-five sections of 20 mm thickness was then collected with a final H&E for confir-
mation of uniformity of tumor content.
DNA was extracted using an automated magnetic bead extraction and purification system according to the manufactures’ proto-
cols (Prepito DNA Tissue10 Kit, Perkin Elmer Ltd, Bucks,UK). DNA from blood was obtained using a column based system (Qiamp
DNA Blood Maxi kit, Qiagen,Manchester,UK). DNA concentration and quality were assessed by a fluorometric assay (Picogreen,
Thermofisher Scientific,Paisley,UK) and a PCR assay followed by gel electrophoresis. Only DNA that was of suitable concentration
(minimum 500 ng total) and was amplifiable were used for whole genome sequencing.
Whole-Genome Sequencing Protocol and Data Processing
Whole genome sequencing was performed on samples on the XTen instrument (Illumina,Chesterford,UK) according to the manufac-
turers protocol using 150 bp, paired-end libraries with a PCR free workflow. The average coverage of tumors was at least 70X and of
normal DNA at least 30X. For classification of genome complexity there was no association between molecular subgroup and tumor
purity (Kruskal Wallis test, p=0.13), suggesting that the relatively low number of mutations in the mutLo-rearrLo subgroup is not an
artefact of normal tissue contamination of the tumor specimens.
Targeted Sequencing Protocol and Data Processing
Genomic DNAwas extracted from formalin fixed paraffin embedded tissues. Samples were chosen based on high tumor content and
cellularity.
We designed a DNA target-enrichment design (SureSelect, Agilent Technologies, Santa Clara, CA, USA). We selected 350 genes
implicated in cancer and/or sarcoma based on the whole genome sequencing results to serve as a validation assay, identify cancer
genes not previously implicated in sarcoma and to assess the frequency of the recurrent mutations.
The bait design also incorporated an Agilent OneSeq 8 Mb copy number backbone evenly spaced across the genome and sup-
plemented by 7000 heterozygous single nucleotide polymorphisms densely tiled across the cancer genes in the assay. DNA and
library preparation was carried out as per the manufacturers protocol. Samples were sequenced on a 150 bp paired end high output
NextSeq runs. Fastq files were aligned to the human genome reference build GRCh37 using BWA mem.
Hypermutation was defined with a decision boundary of 10 mutations/Mb to account for the large number of subclonal mutations;
no rearrangement groups were possible to define for the extension cohort due to the nature of the assay.e2 Cancer Cell 35, 441–456.e1–e8, March 18, 2019
RNA Sequencing Protocol and Data Processing
Total RNA was isolated from frozen tissues using the Zymo Direct Zol RNA isolation kit according to manufacturers’ recommenda-
tions that included the on-column DNase digestion. The quantity and quality of total RNA was assessed by NanoDrop
spectrophotometer (Thermo Scientific), Qubit (Thermo Scientific) and Tapestation (Agilent). Only samples with a RIN score >6,
high quality spectrophotometer rations and RNA concentration > 250 ng were selected for library preparation.
KAPA Stranded mRNA-Seq kit (Roche- KAPA Biosystems) was used to generate indexed Illumina platform sequencing libraries
according to the manufacturer’s instructions. Equimolar amounts of libraries were pooled and sequenced on an Illumina HiSeq
2500 instrument using standard protocols for paired end 100 bp sequencing with a desired sequencing depth of 60 million paired
end reads per library.
Fastq files were aligned to the human genome build GrCh37 using HISAT2 (Kim et al., 2015) and gene expression was quantified
using stringtie (Pertea et al., 2015).
Methylation Protocol
600 ng of fresh frozen DNA were bisulfite converted using the Zymo EZ DNA methylation Gold kit (Zymo Research Corp.Irvine,-
CA,USA) as per manufacturers recommendations. Bisulfite converted samples were processed and hybridized to the Infinium
HumanMethylationEPIC beadchip arrays according to the manufacturer’s recommendations.
Methylation intensities were normalized with noob background correction and functional normalization using the minfi funnorm
function (Aryee et al., 2014) and converted to beta values for downstream analysis. Sex probes, SNP probes and probes with a
detection p-value>0.01 in any sample were removed from the dataset.
Immunohistochemistry Protocol
All staining was performed on the Leica Bond III automated immunostaining platform, with peroxidase blocking and detection
carried out using the Leica Bond Polymer Refine DAB kit (Leica, DS9800, Leica Microsystems, Milton Keynes, UK) according to
manufacturer’s instructions. Dewaxing and epitope retrieval were carried out on board using Leica Bond Dewax (Leica, AR9222)
and Leica Epitope Retrieval solution 1 or 2 (Leica, AR9961, AR9640). Peroxide block (as per kit) was performed for 5 minutes at
ambient temperature prior to primary antibody application. All primary antibodies were diluted in Leica Bond Primary Antibody
Diluent (Leica, AR9352) and applied for 30 minutes at ambient temperature. Rabbit-anti-mouse post-primary and anti-rabbit
polymer (as per kit) were sequentially applied for 20 minutes each before detection with DAB and counterstaining with
hematoxylin.
MLH1
MLH1 (Leica, mouse monoclonal ES05, cat. NCL-L-MLH1): diluted 1/200. Epitope retrieval: ER2 (high pH), 40 minutes, 99C.
MSH2
MSH2 (Agilent Technologies, mouse monoclonal FE11, cat. M363901-2): diluted 1/50. Epitope retrieval: ER2 (high pH),
20 minutes, 99C.
MSH6
MSH6 (Agilent Technologies, rabbit monoclonal EP49, cat. M364601-2): diluted 1/50. Epitope retrieval: ER2 (high pH), 30 mi-
nutes, 99C.
PMS2
PMS2 (BD Biosciences, mouse monoclonal A16-4, cat. 556415): diluted 1/300. Epitope retrieval: ER2 (high pH), 40 minutes, 99C.
ATRX (Sigma-Aldrich, rabbit polyclonal HPA001906): diluted 1/500. Epitope retrieval: ER2 (high pH), 20 minutes,99C.
Fluorescence In-Situ Hybridization Protocol
The alternative lengthening of telomere phenomenon was investigated in the USARC cohort by telomere specific fluorescent in-
situ hybridization using previously described methods. In brief, deparaffinized sections were pre-treated by pressure cooking for
5 minutes and subsequently incubated in pepsin solution at 37C for 50 minutes. Probes (Telomere PNA FISH – FITC; K532511-8;
Agilent Technologies LDA UK Limited, Cheshire, UK) were applied to tissue sections and denatured at 72C, and followed by
hybridization overnight at 37C. After hybridization, the sections were washed and mounted using 40,6-diamidino-2-phenylindole
with coverslips. The telomere phenotype was determined using a published method (Koelsche et al., 2016). This was supple-
mented by assessing area of fluorescent intensity using the Olympus Cell imaging software in a minimum of 10 tumor cells
per case.
Image Cytometry Protocol
Based on amodified protocol of Hedley et al. (1983), 50 mmFFPE sections fromUSARC samples were deparaffinized and rehydrated.
Nuclear suspensions were obtained through cytoplasmic digestion using protease type VIII (Sigma P5380). Samples were filtered,
cytospun, and subjected to DNA hydrolysis (5 M HCl) and Feulgen staining (Schiff’s fuchsin-sulphite reagent; Sigma S5133). DNA
ploidy was measured using the Fairfield ploidy system. A histogram with a DNA index was produced for each sample by calculating
the integrated optical density.Cancer Cell 35, 441–456.e1–e8, March 18, 2019 e3
QUANTIFICATION AND STATISTICAL ANALYSIS
Somatic Mutation Triaging
Mutations were called using CaVEMan (Varela et al., 2011) and cgpPindel (Raine et al., 2015) for whole-genome sequencing. Only
mutations that had median assembly score (ASMD)R140 and median clipped bases (CLPM)=0 were considered reliable mutations.
For targeted sequencing, mutations were called using Mutect2 from GATK v3.8 (Van der Auwera et al., 2013). Mutations were
prioritized after annotating with VEP (McLaren et al., 2016) as follows:
1 Variants observed in the CIVIC (Griffith et al., 2017), Sanger, Genie (AACRProject GENIE Consortium, 2017) or Memorial Sloane
Kettering Cancer Center cancer hotspots database (MSKCC) were categorized as ‘‘High confidence’’.
2 Variants overlapping the Encode Blacklist (Encode Project Consortium, 2012), or that were unidirectional, or were seen in
>1.5% of germline reads were categorized as ‘‘Unreliable’’.
3 Silent variants were retained.
4 Variants observed in the ExAC database (Lek et al., 2016) were categorized as ‘‘Unreliable’’.
5 Variants observed in >1 patient wass categorized as ‘‘Medium confidence’’, otherwise ‘‘Low confidence’’.
6 ‘‘Medium confidence’’ variants were re-categorized as ‘‘Low confidence’’ if CADD score <20, IMPACT=LOW or
IMPACT=MODIFIER, while ‘‘Low confidence’’ variants were re-categorized as ‘‘Medium confidence’’ if CADD score>20, IM-
PACT=HIGH or MODERATE or clinsig=pathogenic.
Potential driver mutations were those defined as ‘‘High confidence’’ or ‘‘Medium confidence’’ (see below).
Germline Mutation Triaging
Germline variants were annotated using VEP. Potentially pathogenic variants were restricted to those in coding regions, including
splice region variants. Variants were considered pathogenic if their clinical significancewas pathogenic, their impact was high or their
CADD score wasR30. Additionally, any variant must have passed the ExAC quality filter.
Rearrangement Triaging
Rearrangements were called using BRASS (Nik-Zainal et al., 2016) for whole-genome sequencing, and Lumpy for targeted
sequencing. Stringent BRASS calls were defined as those that were able to be locally assembled at base pair resolution and
were not observed in the germline.
Rearrangements were then classified as functional (Disruptive or Fusion), or not (Unknown significance or Benign) using BRASS
fusion flags as follows:
1 UTR-UTR, single intron or ambiguous flags were classified as ‘‘Unknown significance’’.
2 Fusion flags with different reading frame fusion between an exon and intron, those within the same gene in different regions,
those that lead to truncation, those that are a rearrangement between an intron and an intergenic region, and those that are
in an opposite orientation between and intron and an exon are classified as disruptive.
3 Those with no predicted fusion, but which have an intronic or exonic breakpoint are classified as disruptive. Otherwise they are
classified as benign.
4 In-frame fusions are classified as fusions.
5 Driver disruptions are identified as those that occur in a COSMIC TSG and are not in the UTR.
6 Driver fusions are categorized as those that include a COSMIC fusion gene, and the fusion partner is also included in COSMIC.
Potential driver rearrangements were identified from the functional rearrangements by cross-referencing with the COSMIC data-
base of known cancer driver genes. Out of 452 predicted fusions involving two genes with unambiguous reading frames, 158 pre-
dicted in-frame fusions were identified in 47 samples involving 14 cancer genes (16), none of which were recurrent. Of the 14 putative
fusions involving known cancer genes, none involved a known fusion partner and no recurrent novel predicted fusion genes were
discovered. Moreover, further interrogation of the predicted breakpoint regions revealed that 39% of them directly overlap a known
fragile site (Bignell et al., 2010).
Copy-Number Calling
Allele specific copy number and ploidy were called using ASCAT NGS (Van Loo et al., 2010) for whole-genome sequencing, and
ASCAT for targeted sequencing. Gene level driver copy number aberrations were identified as such:
Amplification
Minimum total copy number across the gene > 21.33 ploidy in a known cancer amplified gene (COSMIC).
Homozygous Deletion
Any region within a known tumor suppressor gene (COSMIC) has allele specific copy number = {0,0}.
Loss of Heterozygosity
Any region within a known tumor suppressor gene (COSMIC) has allele specific copy number = {0,R1} or {R1,0}.e4 Cancer Cell 35, 441–456.e1–e8, March 18, 2019
Recurrent Rearrangements
Genomic regions containing clustered breakpoints in whole-genome sequencing were found by binning the human genome into
1 Mb bins and counting the number of samples with >1 rearrangement breakpoint as identified by stringent BRASS calls (described
above) in each (Peifer et al., 2015). To determine a suitable threshold above which to call recurrence significant, 10,000 Monte Carlo
simulations of random breakpoint partners were performed as follows:
Let p be the probability of breakpoint partners being on the same chromosome (determined empirically from the dataset). Then:
n  1+Binð1 pÞ;
where n is the number of chromosomes involved in the rearrangement.
Let sc be the start position of the cth chromosome from set C={1,2,.,X,Y}, and ec be the end position.





Bc  Uðsc; ecÞ;
where Bc are the breakpoints drawn from the cth chromosomes.
If instead n=1, then:
D  Expð1=mcÞ;
where D is the distance between the two breakpoints, and mc is the mean distance between breakpoints on the cth chromosome
(determined empirically from the dataset). Then:
B1;c  Uðsc; ec  DÞ;
and:
B2;c =B1;c +D;
where B1,c and B2,c are the 1
st and 2nd breakpoint on chromosome c.
If,O is the set of number of rearrangements observed in all samples in the dataset, then rearrangements are simulated N times as:
N  Gammaðk; qÞÞ:
where k and q are the shape and scale parameters of the gamma distribution, which are estimated from O by maximum likelihood
(fitdistr, R MASS package). For each Monte Carlo simulation, x simulated samples are generated, where x matched the number of
samples in the dataset.
For a genomic bin with i observed samples with breakpoints, the p-value is then (m+1)/(M+1), wherem is the number of simulations

















where P are the ordered p-values. Any Q-value <0.2 was considered significant.
Recurrent Copy Number Alterations
Recurrent copy number alterations from whole-genome sequencing at a gene level (-genegistic) were identified using GISTIC 2.0
(Mermel et al., 2011) with a broad analysis (-broad) and arm level peel off (-armpeel), a threshold for deletions and amplifications
of 0.25 (-ta,-td), a threshold for broad events of 0.98 (-brlen). The confidence level for calculating driver regions was 0.90 (-conf).
Marker-level copy number data was collapsed to gene-level data using the extreme method (-gcm).
Chromothripsis Identification
Regions of chromothripsis were identified using criteria outlined in Korbel and Campbell (2013), namely through clustering of break-
points, randomness of DNA fragment joins and randomness of DNA fragment order. Chromothripsis was interrogated in sliding
windows of 3 Mb, with a spacing of 100 kb. Only chromosomes with >30 breakpoints were considered. A Kolgomorov-Smirnov
test was performed on distances between breakpoints of a whole chromosome (not a sliding window) against the exponential dis-
tribution with mean equal to the mean breakpoint distance, a p-value threshold <0.05 was used as Korbel and Campbell (2013) state
chromothriptic chromosomes have a strong departure from a random distribution. A goodness of fit test was performed on the
counts of {HH, HT, TH, TT} joins with a null distribution of {0.25, 0.25, 0.25, 0.25} to test for random DNA joins in sliding windows.
A monte carlo simulation of 1000 draws of two breakpoints was performed on sliding windows to test random order, where theCancer Cell 35, 441–456.e1–e8, March 18, 2019 e5
p-value was the proportion of simulations where
i1;s  i2;s>i1;d  i2;d where i1,s is the ordered index of the first breakpoint in the
simulated pair of breakpoints, and i1,d is the ordered index of the first breakpoint of a rearrangement pair in the dataset. For random
joins and random order a looser threshold of p>0.8 was used, as these tests are aiming to accept the null rather than reject it, and in
particular Korbel and Campbell (2013) state that the random order of breakpoints is not entirely random, but more random than a
scenario of independent structural rearrangement. If two of the three tests indicated chromothripsis, the window was designated
as a potentially chromothriptic event. Note that these tests are able to identify events that do not behave like classical chromothripsis
(oscillating between two copy number states, one of which is LOH), but share the hallmarks of chromothripsis. A strict definition of
two copy number states was not employed as it precludes copy number alteration preceding or subsequent to chromothripsis, and
chromothripsis events have previously been described that involve >>2 copy number states (Behjati et al., 2017; Garsed et al., 2014;
Stephens et al., 2011). Likewise, a strict definition requiring oscillating between LOH and non-LOH segments was not incorporated,
as it precludes chromothripsis after a WGD event, which is prevalent in our dataset.
Overlapping windows of potentially chromothriptic events were merged. All chromothripsis calls were manually reviewed.
Similar to above, recurrent chromothripsis events were identified by binning the genome into 100 kb bins and counting the number
of samples that had a chromothripsis event overlapping each bin.
Telomere Length Estimation
Telomere lengths were estimated from whole genome sequencing reads with a published tool Telseq and using the authors recom-
mended settings (Ding et al., 2014). The weighted average of reads containing at least 7 instances of the telomeric motif TTAGGG in a
read group was used to estimate the length.
Mutational Signatures
Mutational signatureswere identified using non-negativematrix factorization (NMF) of counts of the triplet context of eachmutation in
each sample (Alexandrov et al., 2018).
Rearrangement Signatures
Rearrangement signatures were identified using NMF of counts of rearrangements in each sample, classified by type (insertion,
deletion, tandem-duplication, translocation), size (1-10 kb, 10 kb-100 kb, 100 kb-1 Mb, 1 Mb-10 Mb, >10 Mb) and whether the re-
arrangement was clustered or unclustered. The method for determining clustered or unclustered rearrangements was altered from
Nik-Zainal et al. (2016); we determine clustered rearrangements as those falling in a piecewise constant fit segment with an
average distance between rearrangements less than 0.1x the mean distance between rearrangements across the data set, rather
than 0.1x themean distance between rearrangements in a given sample as is the case in Nik-Zainal et al. (2016). This avoids samples
with a majority of rearrangements arising from chromothripsis having none of them called as clustered.
Copy Number Signatures
Copy number signatures were identified from ASCAT allele-specific copy number profiles using NMF. Copy number segments were
classified as heterozygous, LOH or homozygous deletions. These were further subclassified by total copy number (0-1=deleted,
2=neutral, 3-4=duplicated, >4=amplified). These were then further subclassified by size of segment (0-0.01 Mb, 0.01-0.1 Mb,
0.1-1Mb, 1-10Mb, >10Mb). This gives a total of 40mutually exclusive categories a segment can be classified as; 20 LOH categories,
15 heterozygous categories and 5 homozygous deletion categories. NMF was run with ranks 2 through 12 for 1000 runs. The appro-
priate rank was selected to maximize the consensus silhouette width, the cophenetic distance and the dispersion of clusters. NMF
was also run for 1000 runs with ranks 2 through 12 on a randomized version of the data to avoid overfitting.
Following NMF, the deconstructSigs R package (Rosenthal et al., 2016) was used to estimate the exposure of each identified
signature in each sample, to reduce overfitting of the exposures to the data.
Validation Cohort
A validation cohort of copy number profiles called by ASCATwere collated from published datasets: 43 chondrosarcoma SNP arrays
(Tarpey et al., 2013), 112 osteosarcomaSNP arrays (Behjati et al., 2017) and 203mixed soft tissue sarcomaSNP arrays (TCGA, 2017).
To these we added 15 low grade and assorted sarcoma whole genomes.
Copy number signatureswere identified in this cohort in the samemanner as for the USARC cohort. Cosine similarities between the
USARC signatures and validation signatures were used to determine if signatures were shared across the two cohorts.
Additionally, thevalidationcohortwasscanned for theoriginalUSARCcopynumbersignaturesusing thedeconstructSigsRpackage.
The diversity of copy number signatures identified in each sample for both the validation cohort and the USARC cohort was quan-





where n is the number of signatures identified in the sample with exposure >0 and pi is the normalized exposure of the ith signature
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The probability of the large-scale LOH occurring before WGD is higher than LOH after WGD (P=0.63 and 0.22 respectively,
assuming independent chromosome segregation over all possibilities of chromosome segregation events in a model given a diploid
or tetraploid cell state).
Survival Analysis
Associations with survival were identified using an accelerated failure time (AFT) model. This model was used because the Cox pro-
portional hazards model’s assumption of proportional hazards is violated by several key covariates: resection margins, metastasis
status, RB1 mutation status and ATRX mutation status. Patients with only non-primary tumor samples were excluded from analysis.
Genetic covariates for a patient with both a primary andmetastasis sample were based on the primary sample only. A log-normal AFT
model was fit to the log survival times of patients.
An AFT model for overall survival was fit with covariates: size of tumor (mm), resection margins (Complete, Marginal, Incomplete),
metastasis status (Metastasis at diagnosis, Metastasis after diagnosis, No metastasis, Unknown) and burden group (mutLo-rearrLo,
mutLo-rearrHi, mutHi-rearrLo).
AFT models for metastasis-free survival and progression-free survival were fit with covariates: size of tumor (mm), resection mar-
gins (Complete, Marginal, Incomplete) and burden group (mutLo-rearrLo, mutLo-rearrHi, mutHi-rearrLo).
Other models were fit with genetic mutations of TP53, ATRX, RB1,CDKN2A and PTEN as extra covariates, but none of these were
significant. Additional clinical covariates that were previouslymodelled but found to be non-significant were age at diagnosis, gender,
recurrence status. Additional genetic covariates that were previously modelled but found to be non-significant were rearrangement
signatures and copy number signatures.
Timing of Whole Genome Duplications
To time whole genome duplications we first inferred the multiplicity of each single nucleotide variant (SNV), i.e. the number of bearing
alleles of the mutation (Dentro et al., 2017). Briefly, the most likely multiplicity of an SNV mSNV, given the purity of the sample r, the
underlying total tumor copy number ntot,t,SNV and the variant allele fraction of the SNV fSNV is the integer bound by the underlying
major allele state of the tumor nmajor ,t,SNV, inferred as:
argminmSNV




where ntot,n,SNV=2 is the total copy number of the normal diploid contaminant. As a second step, we separately time whole genome
duplications (WGD) in samples having undergone a single WGD (WGDx1) and two WGDs (WGDx2):
1) WGDx1: in regions of the genome represented by 2 copies of the major allele and 0 or 2 copies of the minor allele (annotated
2+0 and 2+2), we count the number of SNVs with a multiplicity of 2 N2, i.e. acquired prior to the WGD and the SNVs with a
multiplicity of 1 N1, i.e. acquired posterior to the WGD. We then time the WGD in relative mutational timing tWGD1:





2) WGDx2: similarly toWGDx1, in regions of the genome represented by 4 copies of themajor allele and 0 or 4 copies of theminor
allele (annotated 4+0 and 4+4) we count the number of SNVs with a multiplicity of 4 N4, i.e. acquired prior to the first WGD, a
multiplicity of 2N2, i.e. acquired prior to the secondWGD but posterior to the first, and a multiplicity of 1N1, i.e. late SNVs. We
then time the first and second WGDs in relative mutational timing tWGD1 and tWGD2, resp.:

















We compute the 95% confidence intervals from 1,000 bootstrapping of the multiplicities.
Finally, using the same rationale, i.e. early mutations in duplicated regions appear on all duplicated copies, we infer timing of drivers
relative to the WGDs from their estimated multiplicities, if they fall in 2+2 or 2+0 regions, and 4+0 or 4+4 regions for WGDx1 and
WGDx2, respectively.
To timeWGD in TCGA data, we applied the same concepts as outlined, however, we first selected only samples with a major allele
R2 (Figure S7A), i.e. with at least oneWGD, and for which our ploidy estimatesmatched the ploidy estimates in the TCGA publication
(TCGA, 2017) (Figure S7B). Timing of WGD events further allowed for testing the possibility of an artefactual origin of the mutLo-
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test, p>0.05). Additionally, there was no significant association betweenWGD timing, ploidy or normal contamination with rearrange-
ment count in a multivariate regression, as well as no significant interaction between any of the three variables (all p>0.05).
Real-Time Timing
Following the rationale in Gerstung et al. (2017), we scale the relative mutational timing from 0 to the age at diagnosis of the patients.
As the acceleration rates are unknown, we did not simulate any acceleration rates. Therefore, our timing estimatesmight be later than
if accounting for acceleration of the clock. So, for a given relative timing of e.g. a whole genome duplication tWGD1 in a patient whose
age at diagnosis was a, the real-time timing of the WGD rtWGD1 becomes
rtWGD1 = a3 tWGD1
and the WGD occurred tbdWGD1 years before diagnosis
tbdWGD1 = a rtWGD1
We verified that the number of spontaneous (C>T)pG were correlated with the age at diagnosis (Figure S7C), as well as strongly
correlated with the total number of mutationsNSNV (Figure S7D), andNSNVwere therefore also correlated with the age of the patients
(Figure S7E). Not to lose too many mutations for the real-time estimates of WGD, we used all mutations to derive the relative timing
and real-time timing. In our USARC cohort, we verified that the results using only (C>T)pG , where the numbers were sufficient yielded
very similar estimates and overall picture (Figure S7F). Using all mutations, we could timeWGD in the TCGA exome data, in which the
number of mutations is limited and timing using only (C>T)pG becomes inaccurate or even unfeasible.
Gene Set Enrichment Analysis (GSEA)
We performed GSEA using MSigDB collections (Subramanian et al., 2005): c2 KEGG, c2 REACTOME, c5 CC, c5 MF, c6 ALL. To run
GSEA, one summary value per gene symbol was used. For each gene, we collapsed the matrix of log2 TPM expression values and
thematrix of beta methylation values to themost variable entry. We then selected the 20,000most variable genes across all samples.
We ran two-class GSEA using the signal-to-noise metric with 200 permutations and looked into gene sets with q-value<0.1 (slightly
stricter than GSEA recommendation q-value<0.25).
Linear Modelling of Gene Expression
Linear models of gene expression against independent variables were explored for TP53,RB1,CDKN2A,ATRX,PTEN,MEN1, TERT,
MSH6, MSH2 and MBD4. Initial models were parameterized as:
g= b0 + b1p+ b2c;
where g is gene expression, p is tumor purity and c is minimum gene copy number. These models were further expanded to include
methylation probe beta values, m, as dependent variables:
g= b0 + b1p+ b2c+ b3m:
The p-values for copy number from the initial models were corrected for multiple testing over 10 genes, while the p-values for
methylation probe beta values were corrected for multiple testing over 402 probes.
Statistical Analysis
All statistical analysis was performed using R (R Core Team, 2017). Survival analysis was performed using the survival (Therneau and
Grambsch, 2000) and flexsurv (Jackson, 2016) packages. NMFwas performed using theNMF (Gaujoux and Seoighe, 2010) package.
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The accession number for the whole genome sequencing reported in this paper is deposited in EGA database at EMBL-EBI (https://
www.ebi.ac.uk/ega/about/access) under accession number EGAD00001004162.
The accession number for themethylation array data reported in this paper is deposited in the ArrayExpress database at EMBL-EBI
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-6961.
The accession number for the RNA sequencing data reported in this paper is deposited in EGA database under accession number
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